Johnson & Johnson (NYSE:JNJ) is Cheviot Value Management LLC's 5th Largest Position

Cheviot Value Management LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 9.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 155,318 shares of the company's stock after buying an additional 13,823 shares during the quarter. Johnson & Johnson comprises about 4.3% of Cheviot Value Management LLC's holdings, making the stock its 5th largest position. Cheviot Value Management LLC's holdings in Johnson & Johnson were worth $22,462,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of JNJ. IFS Advisors LLC raised its position in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares during the last quarter. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson in the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $32,000. Finally, Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $33,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of JNJ traded down $0.39 during mid-day trading on Friday, reaching $154.54. 8,642,889 shares of the stock traded hands, compared to its average volume of 7,928,484. The company has a market cap of $371.83 billion, a price-to-earnings ratio of 23.24, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a fifty day moving average price of $159.48 and a 200 day moving average price of $154.84. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.36%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

Analysts Set New Price Targets

A number of research analysts have issued reports on JNJ shares. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Raymond James dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Finally, Stifel Nicolaus decreased their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $171.82.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.